JPMorgan Downgrades ChemoCentryx (CCXI) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts CCXI Hot Sheet
Price: $10.69 +15.07%
Rating Summary:
4 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Rating Summary:
4 Buy, 10 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Join SI Premium – FREE
JPMorgan analyst Anupam Rama downgraded ChemoCentryx (NASDAQ: CCXI) from Overweight to Neutral with a price target of $15.00 (from $14.00).
The analyst steps the sidelines given anticipation for continued progress coupled with a range-bound stock valuation over the NT due to a lack of catalysts.
For an analyst ratings summary and ratings history on ChemoCentryx click here. For more ratings news on ChemoCentryx click here.
Shares of ChemoCentryx closed at $12.67 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- JPMorgan Downgrades Group 1 Automotive Inc. (GPI) to Underweight
- Jefferies Downgrades Haleon PLC (HLN:LN) (HLN) to Hold
- Berenberg Starts GomSpace Group AB (GOMX:SS) at Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change, DowngradesRelated Entities
JPMorganSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
